Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
1 finding from 1 review
Relapse · Participants with Crohn's disease in remission
Usual care showed no clear difference in relapse at 12 or 24 months compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline showed no clear difference in smoking abstinence at longest compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline showed no clear difference in SAEs compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
Varenicline showed no clear difference in neuropsychiatric SAEs compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
Cardiac SAEs · people who smoke
Varenicline showed no clear difference in cardiac SAEs compared with combination nicotine replacement therapy (low certainty).
1 finding from 1 review
Six‐minute walk distance · pulmonary arterial hypertension
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).
1 finding from 1 review
Physical functioning component of health‐related quality of life, measured using various scales · pulmonary arterial hypertension
1 finding from 1 review
PAP · pulmonary arterial hypertension
1 finding from 1 review
Cardiac output · pulmonary arterial hypertension
1 finding from 1 review
PVR · pulmonary arterial hypertension
1 finding from 1 review
Improvement in WHO functional class · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).
1 finding from 1 review